Literature DB >> 31470255

Major depressive disorder is associated with changes in a cluster of serum and urine biomarkers.

Erin M van Buel1, Marcus J M Meddens2, Eduard A Arnoldussen2, Edwin R van den Heuvel3, Willem C Bohlmeijer4, Johan A den Boer5, Anna Muller Kobold6, Leandra J M Boonman-de Winter7, Dirk van Rumpt8, Lambertus F J Timmers9, Mattheus F A Veerman10, Johannes S Kamphuis11, Anatoliy V Gladkevich6, Robert A Schoevers12, Paul G M Luiten13, Ulrich L M Eisel1, Fokko J Bosker6, Hans C Klein14.   

Abstract

Major Depressive Disorder (MDD) is a heterogeneous disorder with a considerable symptomatic overlap with other psychiatric and somatic disorders. This study aims at providing evidence for association of a set of serum and urine biomarkers with MDD. We analyzed urine and serum samples of 40 MDD patients and 47 age- and sex-matched controls using 40 potential MDD biomarkers (21 serum biomarkers and 19 urine biomarkers). All participants were of Caucasian origin. We developed an algorithm to combine the heterogeneity at biomarker level. This method enabled the identification of correlating biomarkers based on differences in variation and distribution between groups, combined the outcome of the selected biomarkers, and calculated depression probability scores (the "bio depression score"). Phenotype permutation analysis showed a significant discrimination between MDD and euthymic (control) subjects for biomarkers in urine (P < .001), in serum (P = .02) and in the combined serum plus urine result (P < .001). Based on this algorithm, a combination of 8 urine biomarkers and 9 serum biomarkers were identified to correlate with MDD, enabling an area under the curve (AUC) of 0.955 in a Receiver Operating Characteristic (ROC) analysis. Selection of either urine biomarkers or serum biomarkers resulted in AUC values of 0.907 and 0.853, respectively. Internal cross-validation (5-fold) confirmed the association of this set of biomarkers with MDD.
Copyright © 2019. Published by Elsevier Inc.

Entities:  

Keywords:  Biomarker panel; Biomarkers; ELISA; Major depressive disorder; Permutation analysis; Urine

Year:  2019        PMID: 31470255     DOI: 10.1016/j.jpsychores.2019.109796

Source DB:  PubMed          Journal:  J Psychosom Res        ISSN: 0022-3999            Impact factor:   3.006


  4 in total

1.  Gender Differences in Developing Biomarker-Based Major Depressive Disorder Diagnostics.

Authors:  Mike C Jentsch; Huibert Burger; Marjolein B M Meddens; Lian Beijers; Edwin R van den Heuvel; Marcus J M Meddens; Robert A Schoevers
Journal:  Int J Mol Sci       Date:  2020-04-25       Impact factor: 5.923

2.  Combined serum IL-6, C-reactive protein, and cortisol may distinguish patients with anhedonia in major depressive disorder.

Authors:  Yinghui Li; Yingying Yue; Suzhen Chen; Wenhao Jiang; Zhi Xu; Gang Chen; Zixin Zhu; Liangliang Tan; Yonggui Yuan
Journal:  Front Mol Neurosci       Date:  2022-08-24       Impact factor: 6.261

3.  New challenges in the COVID-19 pandemic.

Authors:  Jess G Fiedorowicz
Journal:  J Psychosom Res       Date:  2020-04-22       Impact factor: 3.006

4.  Potential biomarkers of major depression diagnosis and chronicity.

Authors:  Ana Cecília de Menezes Galvão; Raíssa Nobrega Almeida; Geovan Menezes de Sousa Júnior; Mário André Leocadio-Miguel; Fernanda Palhano-Fontes; Dráulio Barros de Araujo; Bruno Lobão-Soares; João Paulo Maia-de-Oliveira; Emerson Arcoverde Nunes; Jaime Eduardo Cecilio Hallak; Jerome Sarris; Nicole Leite Galvão-Coelho
Journal:  PLoS One       Date:  2021-09-29       Impact factor: 3.240

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.